Positive top-line Phase 2B/3 results for masitinib in progressive forms of MS
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
FDA green-lights U.S. patient enrollment in masitinib phase 3 study in metastatic castrate-resistant prostate cancer
08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
Publication of new results in in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
Publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
Webcast on masitinib in severe asthma on Monday, December 2, 2019
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
AB Science Corporate Presentation
AB Science Corporate Presentation
Positive top-line Phase 3 results for masitinib in severe asthma
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA